APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOKApyxMedical2025-12-12T19:14:42+00:00August 11, 2022|Read More
APYX MEDICAL CORPORATION RELEASES ENVIRONMENTAL, SOCIAL AND GOVERNANCE DATA IN NEW TEAR SHEETApyxMedical2025-12-12T19:15:08+00:00July 27, 2022|Read More
RENUVION CLEARED BY FDA FOR NECK LAXITY PROCEDURES OFFERING PATIENTS A MINIMALLY INVASIVE OPTION TO ELIMINATE SAGGING NECKApyxMedical2025-12-12T19:15:31+00:00July 18, 2022|Read More
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO IMPROVE APPEARANCE OF LAX (LOOSE) SKINApyxMedical2025-12-12T19:15:55+00:00July 18, 2022|Read More
APYX MEDICAL CORPORATION ANNOUNCES RESULTS OF THE U.S. IDE CLINICAL STUDY EVALUATING THE USE OF RENUVION TO IMPROVE THE APPEARANCE OF LAX SKIN IN THE NECK AND SUBMENTAL REGIONApyxMedical2025-12-12T19:16:26+00:00July 8, 2022|Read More
APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON AUGUST 11, 2022ApyxMedical2025-12-12T19:16:50+00:00June 30, 2022|Read More
RENUVION DERMAL HANDPIECE FOR WRINKLE-REDUCTION PROCEDURES CLEARED BY FDAApyxMedical2025-12-12T19:17:12+00:00June 28, 2022|Read More
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION COSMETIC TECHNOLOGY IN DERMAL RESURFACING PROCEDURESApyxMedical2025-12-12T19:17:54+00:00May 26, 2022|Read More
APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN JUNEApyxMedical2025-12-12T19:18:17+00:00May 25, 2022|Read More
APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOKApyxMedical2025-12-12T19:18:44+00:00May 12, 2022|Read More
APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON MAY 12, 2022ApyxMedical2025-12-12T19:19:07+00:00April 4, 2022|Read More
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION WITH CLINICAL STUDY SUPPORT FOR THE USE OF THE RENUVION APR HANDPIECE FOR AESTHETIC PROCEDURES TO IMPROVE APPEARANCE OF LAX SKINApyxMedical2025-12-12T19:19:32+00:00April 4, 2022|Read More
APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2022 FINANCIAL OUTLOOKApyxMedical2025-12-12T19:20:04+00:00March 17, 2022|Read More
APYX MEDICAL CORPORATION NOTIFIED OF PENDING FDA MEDICAL DEVICE SAFETY COMMUNICATION RELATED TO ITS ADVANCED ENERGY PRODUCTSApyxMedical2025-12-12T19:20:29+00:00March 14, 2022|Read More
APYX MEDICAL CORPORATION ANNOUNCES PEER-REVIEWED PUBLICATION FEATURING RESULTS FROM THE U.S. IDE CLINICAL STUDY EVALUATING THE RENUVION DERMAL HANDPIECE USING APYX’S HELIUM PLASMA TECHNOLOGY FOR DERMAL RESURFACING PROCEDURESApyxMedical2025-12-12T19:27:53+00:00February 17, 2022|Read More
APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS ON MARCH 17, 2022ApyxMedical2025-12-12T19:21:22+00:00January 27, 2022|Read More
